Hypertension of neurogenic origin: effect of microvascular decompression of the CN IX–X root entry/exit zone and ventrolateral medulla on blood pressure in a prospective series of 48 patients with hemifacial spasm associated with essential hypertension

Marc Sindou, MD, DSc,1 Mohamed Mahmoudi, MD,1,2 and Andrei Brînzeu, MD1,3

1Department of Neurosurgery, University of Lyon 1, Hôpital Neurologique “Pierre Wertheimer,” Lyon, France; “Section of Neurosurgery, Regional Military Hospital of Oran (HMRUO), Oran, Algeria; and “University of Medicine “Victor Babes,” Timisoara, Romania

OBJECT In spite of solid anatomical and physiological arguments and the promising results of Jannetta in the 1970s, treating essential hypertension by microvascular decompression (MVD) of the brainstem has not gained acceptance as a mainstream technique. The main reason has been a lack of established selection criteria. Because of this, the authors’ attempts have been limited to patients referred for MVD for hemifacial spasm (HFS) who also had hypertension likely to be related to neurovascular compression (NVC).

METHODS Of 201 patients referred for HFS, 48 (23.8%) had associated hypertension. All had high-resolution MR images that demonstrated NVC. All underwent MVD of the root exit/entry zone (REZ) of the ninth and tenth cranial nerves (CN IX–X) and adjacent ventrolateral medulla in addition to the CN VII REZ. Effects on hypertension, graded using the WHO classification, were studied up to the latest follow-up, which was 2–16 years from the time of surgery, 7 years on average. Also, effects of MVD on blood pressure (BP) according to the side of vascular compression were evaluated.

RESULTS Preoperatively, hypertension was severe in all but 1 of the patients; in spite of medical treatment, 47 patients still had WHO Grade 1 or 2 hypertension, and 18 still had unstable BP. After MVD, at latest follow-up, BP had returned to normal (i.e., systolic pressure < 140 mm Hg) in 28 patients; 14 of these patients (29.10% of the whole series) were able to maintain normal BP without any antihypertensive treatment; the other 14 still required some medication to maintain their BP below 140 mm Hg (p < 0.0001). Also, at latest follow-up, BP remained unstable in only 8 of the 18 patients with instability prior to MVD (p < 0.02).

Analysis according to side of compression showed that of the 30 patients with left-sided compression, 17 had their BP normalized (without medication in 11 cases), and of the 18 patients with right-sided compression, 11 had their BP normalized (without medication in 3 cases). The difference between sides was not significant.

CONCLUSIONS These results argue for considering MVD for the treatment of hypertension likely to be due to NVC at the CN IX–X REZ and adjacent ventrolateral medulla. Criteria for selecting patients with hypertension alone still need to be established and could include the following indications: apparently essential hypertension, likely to be neurogenic, in patients in whom high-resolution MRI shows clear-cut images of NVC at the CN IX–X REZ and adjacent ventrolateral medulla and in whom BP cannot be controlled by medical treatment.


KEY WORDS essential arterial hypertension; glossopharyngeal nerve; medulla oblongata; microvascular decompression; neurovascular compression; neurogenic mechanism of hypertension; vagus nerve; functional neurosurgery
EUROVASCULAR compression (NVC) of the ventrolateral medulla was postulated to be a cause, among others, of essential hypertension by Janetta’s group in the late 1970s. Since then only a few studies on this cause and its treatment, either clinical or experimental, have been reported in the literature despite the possibility that such a neurogenic mechanism might be implicated in a relatively large number of patients. The literature affords robust anatomical/physiological evidence that compression of the ninth and tenth cranial nerve (CN IX–X) root entry/exit zone (REZ) and adjacent ventrolateral medulla—especially on the left side, known to convey inputs from the baroreceptors of the (left-sided) cardiac atrium—could be the origin of systemic arterial hypertension.

In the quest for patients affected with essential hypertension to be candidates for vascular decompression, as many as 14 studies have been conducted to investigate the reliability of MRI for the detection of compressive vessels with a potential role in the genesis of hypertension. In most of these publications, images of vascular contact/compression at the ventrolateral medulla were reported at a higher rate in patients with hypertension than in those with normal blood pressure (BP). However, statistical significance was absent when the analysis was restricted to prospective studies.

Because of the absence of established criteria for surgical exploration of the posterior fossa and vascular decompression in patients with only hypertension, apparently essential, we began treating hypertension with microvascular decompression (MVD) only in patients with primary hemifacial spasm (HFS) associated with hypertension. Surgery consisted of performing MVD at the ventrolateral medulla and the CN IX–X REZ in addition to the CN VII REZ. The effects of MVD on BP in this group of patients is the subject of the present report.

**Methods**

**Patient Selection**

Patients included in the study fulfilled the following criteria. 1) Primary HFS (i.e., strictly unilateral) with typical clinical presentation, without any specific etiology determined by ophthalmological, otوروhinolaryngological, and cervicomaxillofacial inventories or MRI exploration, and confirmed to be of a non-postparalytic nature according to the results of electroneuromyographic (ENMG) examination. 2) Essential hypertension according to the International WHO classification—i.e., Grade 1 for systolic BP of 140–159 mm Hg and a baseline diastolic pressure greater than 90 mm Hg. Both the systolic and the diastolic values were regularly measured and transmitted by the patient's GP, according to the patient's usual ones, acknowledged in determining grades; when there was any hesitation in choosing between grades, for simplification and coordination reasons, the decision was made not to discontinue or modify medications for MVD surgery.

For the postoperative study, BP values were the ones regularly measured and transmitted by the patient’s GP.

**Assessment of the Effects of MVD on BP**

All of the enrolled patients with hypertension had a documented follow-up of at least 2 years. For the study, data were collected by an independent observer (M.M.) through a telephone interview of the patient and if necessary the general practitioner (GP).

All patients in the series were being treated with antihypertensive medications at the time they were referred for surgical treatment of HFS. For safety (and also methodological reasons), the decision was made not to discontinue or modify medications for MVD surgery.

Preoperative BP values were measured at rest the day before surgery. Measurements were taken by the admission nurse, with a delay of several hours after arrival of the patient. The measurements were considered valid in all cases in this series because they were in general agreement with the BP values considered the usual ones, according to the GP’s letter of referral.

For the postoperative study, BP values were the ones regularly measured and transmitted by the patient’s GP.

The degree of severity of hypertension was graded according to the International WHO classification—i.e., Grade 1 for systolic BP of 140–159 mm Hg, Grade 2 for systolic BP 160–179 mm Hg, Grade 3 for systolic BP > 180 mm Hg. Both the systolic and the diastolic values were considered in determining grades; when there was any hesitation in choosing between grades, for simplification the systolic value was preferably retained. Also the stable or unstable character of the hypertension as reported by the GP was noted.

For each patient, antihypertensive medication, of all classes, as well as any withdrawal or eventual modifications between preoperative evaluation and latest follow-up interview, was recorded.
Effects of MVD on hypertension were calculated by comparing preoperative BP values (obtained while patients were being treated with antihypertensive medication) and BP values obtained at the most recent postoperative follow-up evaluation. The effect of MVD on hypertension was also evaluated according to the side of the vascular decompression.

Assessment of the Effects of MVD on HFS

Assessment of the effects on the HFS was performed by the senior surgeon (M.S.) at discharge, on average the 10th postoperative day, and then at the first outpatient visit, 2–3 months after the surgery. Also at the first outpatient visit all patients had an ENMG exploration of the facial nerve, performed by the same neurologist who performed the preoperative ENMG examination. Clinical evaluation and ENMG examination were repeated at 1 year in all cases, and additional follow-up (continuing past the 1st year) was provided for patients who did not obtain an early satisfactory result. The final 2012 evaluation was made by the independent observer (M.M.) through telephone interview.

The effect was considered excellent (Class Ia) when there was no residual spasm and the ENMG did not show any ephaptic abnormalities and good (Class Ib) when the patient estimated that he or she was no longer disturbed by the disease in spite of occasional twitches under intense emotional events and/or still had some synkinetic activity at ENMG exploration. Relief that qualified as excellent or good was regrouped as “satisfactory outcome.”

The effect was considered fair (Class II) when bothersome twitches persisted in spite of an overall improvement (in intensity and frequency) of 50% or more.

The effect was considered poor (Class III) when relief was less than 50%, leaving disabling manifestations, and nil (Class IV) when there was no improvement. Poor effect and no effect were regrouped as failure.

Statistical Study

Data were presented as numbers of patients (%) and were compared between the cohorts of patients with and without hypertension by means of the chi-square test or Fisher exact test. Paired comparisons were performed using the paired t-test or Bhapkar test.

Results

From early 1995 to the end of 2009 a total of 201 patients were referred with the diagnosis of primary HFS and underwent MVD of CN VII after MRI demonstrated clear-cut vascular compression(s) at the REZ. Of those patients, 48 (23.9%) also had hypertension that was considered essential. In addition to MVD of CN VII, these patients all underwent decompression of the ipsilateral CN IX–X and neighboring ventrolateral medulla. Only this group of 48 patients was enrolled for the study of the effects of MVD on hypertension. Demographic characteristics and anatomical findings at surgery, namely compressive vessels, were compared between the group of 48 patients with HFS and hypertension and the group of 153 patients with HFS without hypertension. As shown in Table 1, there was no statistically significant difference between the 2 groups with respect to demographic characteristics. As regards compressive vessels, predominance of a posteroinferior cerebellar artery in the group of patients with hypertension had a tendency toward significance.

Demographic Features of the Patients With Hypertension

At surgery, the age of the 48 patients with hypertension ranged from 35 to 82 years (average 59 years). Twenty-six (54.16%) of the patients were male and 22 (45.83%) were female (Table 1).

Characteristics of the HFS

The duration of symptoms (HFS) prior to surgery ranged from 2 to 20 years (average 5 years). According to selection criteria, the spasm was primary, typical, and severely disabling after an average of 5 years of evolution. Spasms were on the left side in 30 patients (62.50%) and on the right in 18 (37.50%). Thirty-five patients (72.9%) had had Botulinum toxin injections, to which they became resistant or intolerant. The 13 others had preferred to undergo surgery without initially trying Botulinum toxin therapy.

Characteristics of the Hypertension

The 48 enrolled patients had chronic, apparently es-

### TABLE 1. Demographic characteristics and anatomical findings (compressive vessels) at surgery in the groups of patients with HFS with and without hypertension*

<table>
<thead>
<tr>
<th>Variable</th>
<th>HFS w/ HT (n = 48)</th>
<th>HFS w/o HT (n = 153)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td></td>
<td></td>
<td>NS</td>
</tr>
<tr>
<td>Female</td>
<td>22 (46)</td>
<td>89 (58)</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>26 (54)</td>
<td>64 (42)</td>
<td></td>
</tr>
<tr>
<td>Age in yrs</td>
<td></td>
<td></td>
<td>NS</td>
</tr>
<tr>
<td>Range</td>
<td>35–82</td>
<td>30–80</td>
<td></td>
</tr>
<tr>
<td>Average</td>
<td>60</td>
<td>53</td>
<td></td>
</tr>
<tr>
<td>Side</td>
<td></td>
<td></td>
<td>0.8315</td>
</tr>
<tr>
<td>Right</td>
<td>18 (37.5)</td>
<td>60 (39)</td>
<td></td>
</tr>
<tr>
<td>Left</td>
<td>30 (62.5)</td>
<td>93 (61)</td>
<td></td>
</tr>
<tr>
<td>Compressive vessel(s)</td>
<td></td>
<td></td>
<td>0.0036</td>
</tr>
<tr>
<td>VA/BA</td>
<td>2 (4)</td>
<td>41 (27)</td>
<td></td>
</tr>
<tr>
<td>PICA</td>
<td>12 (25)</td>
<td>31 (20)</td>
<td></td>
</tr>
<tr>
<td>AICA</td>
<td>15 (31)</td>
<td>24 (16)</td>
<td></td>
</tr>
<tr>
<td>AICA + PICA</td>
<td>5 (10)</td>
<td>19 (12)</td>
<td></td>
</tr>
<tr>
<td>VA/BA + PICA</td>
<td>10 (21)</td>
<td>16 (10)</td>
<td></td>
</tr>
<tr>
<td>VA/BA + AICA</td>
<td>1 (2)</td>
<td>14 (9)</td>
<td></td>
</tr>
<tr>
<td>VA/BA + PICA + AICA</td>
<td>3 (6)</td>
<td>8 (5)</td>
<td></td>
</tr>
<tr>
<td>Implicated vessel (alone or in association)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>VA/BA</td>
<td>16 (33)</td>
<td>79 (52)</td>
<td>0.0267</td>
</tr>
<tr>
<td>PICA</td>
<td>30 (63)</td>
<td>74 (48)</td>
<td>0.0873</td>
</tr>
<tr>
<td>AICA</td>
<td>24 (50)</td>
<td>65 (42)</td>
<td>NS</td>
</tr>
<tr>
<td>Presence of multiple conflicts</td>
<td>19 (40)</td>
<td>57 (37)</td>
<td>NS</td>
</tr>
</tbody>
</table>

NS = not significant.
* Data are given as numbers of cases (%) unless otherwise indicated.
sential, hypertension. At origin, before the introduction of antihypertensive medication, the hypertension was classified as WHO Grade 1 in 22 cases (45.83%), Grade 2 in 22 (45.83%), and Grade 3 in 4 (8.33%) (Table 2). Of the 48 patients, 39 (80.13%) had unstable BP (Table 2 and Fig. 1).

All 48 patients were treated by their GP and if necessary a cardiologist, according to national health recommendations. At the time of the surgery, 15 patients (31.25%) were being treated with a single class of antihypertensive drug, 29 (60.42%) were being treated with 2 classes, and 4 (8.33%) were receiving tritherapy.

Under medical treatment, BP values had improved in a majority of patients. However, in spite of apparently well-conducted treatment, basal BP values stayed higher than normal—WHO Grade 1 in 38 patients and WHO Grade 2 in 9 (Table 2). However, overall average WHO grade was diminished from 1.63, before, to 1.19, after initiation of antihypertensive treatment (Table 2). In spite of the medical treatment, BP remained unstable in 18 of the 39 patients who had unstable BP at diagnosis of hypertension (Table 2 and Fig. 1). In summary, at the time of the surgery, on medication, only 1 patient (2.08%) had systolic BP in the normal range (i.e., under 140 mm Hg), 38 patients (79.10%) had Grade 1 hypertension, 9 (18.75%) had Grade 2 hypertension, and none had Grade 3.

Findings at Surgery

A detailed list of the compressive vessels found at surgery is given in Table 1. Among the 48 patients, 19 (39.50%) had more than 1 compressive vessel. The vertebral artery (VA) and/or basilar artery (BA) was implicated in 16 (33.33%) of the 48 patients, the posterior inferior cerebellar artery (PICA) in 30 (62.50%), and the anterior inferior cerebellar artery (AICA) in 24 (50%). In all of the 48 patients, the conflicting vessels exerted the compressive effect ventrally at the REZ of both the facial nerve and the neighboring CN IX–X rootlets and adjacent ventrolateral medulla.

TABLE 2. Results of MVD on hypertension at latest follow-up, according to the WHO classification

<table>
<thead>
<tr>
<th>BP (mm Hg)</th>
<th>At Dx</th>
<th>Pre-MVD</th>
<th>Post-MVD</th>
<th>p Value†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Category</td>
<td>of HT</td>
<td></td>
<td></td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Normal: &lt;140</td>
<td>0 (0)</td>
<td>1 (2)</td>
<td>28 (58)†</td>
<td></td>
</tr>
<tr>
<td>Grade 1 HT: 140–159</td>
<td>22 (46)</td>
<td>38 (79)</td>
<td>18 (38)</td>
<td></td>
</tr>
<tr>
<td>Grade 2 HT: 160–179</td>
<td>22 (46)</td>
<td>9 (19)</td>
<td>1 (2)</td>
<td></td>
</tr>
<tr>
<td>Grade 3 HT: &gt;180</td>
<td>4 (8)</td>
<td>0 (0)</td>
<td>1 (2)</td>
<td></td>
</tr>
<tr>
<td>Averaged WHO grade</td>
<td>1.63</td>
<td>1.19</td>
<td>0.48</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Unstable</td>
<td>39 (80)</td>
<td>18 (38)</td>
<td>8 (16)</td>
<td>0.02</td>
</tr>
</tbody>
</table>

Dx = diagnosis; HT = hypertension
* Data are presented as numbers of patients (%). BP values are systolic. All pre-MVD BP measurements were obtained with patients on antihypertensive medication. Post-MVD BP is based on measurements obtained at the latest follow-up evaluation.
† Of the 28 patients with normal systolic BP after MVD, 14 were not taking any antihypertensive medication, 10 were following a reduced treatment regimen, and 10 were following the same treatment regimen as before surgery.
‡ Based on Bhapkar test for qualitative scoring and paired t-test for average score.

Effects of MVD on Hypertension

All 48 enrolled patients had at least 2 years of documented follow-up. Forty-four patients were directly accessible through telephone interview at the time of the study. Two patients had died (3 years after MVD in 1 case and 5 years after MVD in the other) and information was provided by their relatives. In both cases, death was due to a disease that had developed subsequent to the MVD procedure and was unrelated to either that procedure or hypertension. Two patients had been lost to follow-up by the time of the study, but adequate information was available for at least 2 years after surgery (2 years in 1 case and 3 years in the other).

Table 2 shows favorable effects of MVD on BP. At the most recent follow-up evaluation (an average of 7 years after MVD, range 2–16 years), BP was normal (systolic pressure < 140 mm Hg) in 28 patients—that is, in 58.33% of the series (p < 0.0001). Of the 28 patients in whom BP had normalized, 14 (29.10% of the whole series) had their antihypertensive treatment totally withdrawn, whereas the 14 others (29.10%) were still being treated with antihypertensive medication, but with a reduced regimen in 10 cases. Treatment was considered notably reduced when at least 1 class of medication could be suppressed from the association of several classes and/or doses of the medications were diminished by at least half, globally.

Also, at the latest post-MVD follow-up, the average WHO grade was decreased to 0.48 from 1.19, the value prior to surgery calculated from BP measurements obtained when patients were under medical treatment (p < 0.0001) (Table 2).

In addition, Fig. 1 shows that after MVD the number of patients with unstable BP was reduced, namely from 18 patients (37.50%) before MVD (under medical treatment) to 8 patients (16.67%) after MVD (p = 0.00038).

The effects of MVD on hypertension according to the preoperative grade of treated hypertension were as follows at latest follow-up. Among the 38 patients with Grade 1 BP, preoperative Grade 1 BP normalized in 23 patients (61.29%) but remained at the same Grade 1 level as before MVD in 15, with the necessity of continuing antihyperten-
sive medication. Of the 9 patients with preoperative Grade 2 hypertension, 4 experienced normalization of BP (gaining 2 classification levels) and 3 experienced improvement to Grade 1; of the other 2 patients, one continued to have Grade 2 hypertension, and in the other, the grade of hypertension rose to Grade 3.

The effects of MVD on BP over time were evaluated by comparing WHO grades at 1 year after surgery and at latest follow-up. The results show a favorable delayed effect in a number of patients; in 8 patients, BP shifted to normal after the 1st year of follow-up (Fig. 2).

The effects of MVD on BP were also evaluated according to the side of vascular compression (Table 3). Thirty (62.50%) of the 48 patients had surgery on the left side and 18 (37.50%) on the right. As shown in Table 3, BP had normalized at latest follow-up in 17 of the 30 patients with left-sided compression; in 11 of these 17, antihypertensive medication could be withdrawn, while in the 6 others, treatment was maintained but at reduced doses. Among the 18 patients with right-sided compression, at latest follow-up BP had normalized in 11; in 3 of these 11, antihypertensive medication could be withdrawn, while in the 8 others treatment was maintained. The difference between sides was not statistically significant (p = 0.14).

Effects of MVD on HFS

The effects of MVD on HFS over time—up to the latest follow-up, 2–16 years (average 7 years) after surgery—are summarized in Table 4. The degree of relief at the latest follow-up was classified as Ia (excellent) in 34 patients (70.83%) and Ib (good) in 8 (16.66%), which corresponds to an overall satisfactory effect (Class I) in 87.50% (42 patients). A fair outcome (Class II) was observed in 2 patients (4.16%). A poor outcome (Class III) and no relief at all (Class IV), both considered failure, was recorded in 8.32% of cases (2 patients having results in each of these 2 categories).

Delayed improvement and recurrence were seen in 8 and 2 patients, respectively. Thus, although a satisfactory effect was observed in 75% of the patients at discharge and in 79.17% at the first outpatient visit, the rate of satisfactory effect increased to 87.50% at the latest follow-up. For the 8 patients who had a delayed satisfactory effect (16.66% in the series), improvement appeared within the 1st year in 6 and as late as the term of the 3rd postoperative year in 2. Conversely a true recurrence—that is, reappearance of a disabling spasm after an initial satisfactory outcome at the first outpatient visit—was observed in 2 patients (4.14%).

Complications of Surgery

Complications of surgery in the 48 patients are listed in Table 5. There was no mortality. Permanent neurological disturbances included swallowing difficulty and vocal cord paresis (occurring at a rate of 2%), hearing deficit (4%), and equilibrium disturbance (2%).

Discussion

The present results suggest a favorable influence of vascular decompression on hypertension due to NVC in the CN IX–X REZ and adjacent medulla. In our series of 48 patients, hypertension was severe in most cases, as shown in Table 2, and frequently unstable, as shown in Fig. 1. In all but one of the patients, hypertension was of Grade 1 or worse in spite of an apparently well-conducted medical treatment. After MVD, at latest follow-up, BP was normalized in 28 patients (58.33%) (p < 0.0001). Medication could be totally withdrawn in 14 of these 28 patients and substantially reduced in more than two-thirds of the 14 others. In addition, MVD significantly decreased BP instability, as shown in Fig. 1 (p = 0.00038).

### Table 3. Effects of MVD on hypertension, according to side of compression and surgery

<table>
<thead>
<tr>
<th>Outcome</th>
<th>Left Side (n = 30)</th>
<th>Right Side (n = 18)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normalization w/ no need for medication</td>
<td>11 (36.7)</td>
<td>3 (16.7)</td>
</tr>
<tr>
<td>Normalization w/ medication (at lower doses)</td>
<td>6 (20.0)</td>
<td>8 (44.4)</td>
</tr>
<tr>
<td>No normalization</td>
<td>13 (43.3)</td>
<td>7 (38.9)</td>
</tr>
</tbody>
</table>

* Values are numbers of patients (%). There was no significant difference with respect to side (p = 0.1422).

### Table 4. Degree of relief of HFS after MVD

<table>
<thead>
<tr>
<th>Effect of MVD</th>
<th>At Discharge</th>
<th>At 1st Outpatient Visit</th>
<th>At Latest Follow-Up†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Satisfactory</td>
<td>36 (75)</td>
<td>38 (79.2)</td>
<td>42 (87.5)</td>
</tr>
<tr>
<td>Excellent (Ia)</td>
<td>21 (43.8)</td>
<td>32 (66.7)</td>
<td>34 (70.8)</td>
</tr>
<tr>
<td>Good (Ib)</td>
<td>15 (31.2)</td>
<td>6 (12.5)</td>
<td>8. (16.7)</td>
</tr>
<tr>
<td>Fair (II)</td>
<td>10 (20.8)</td>
<td>7 (14.6)</td>
<td>2 (4.2)</td>
</tr>
<tr>
<td>Failure</td>
<td>2 (4.2)</td>
<td>3 (6.3)</td>
<td>4 (8.3)</td>
</tr>
<tr>
<td>Poor (III)</td>
<td>0 (0)</td>
<td>1 (2.1)</td>
<td>2 (4.2)</td>
</tr>
<tr>
<td>Nil (IV)</td>
<td>2 (4.2)</td>
<td>2 (4.2)</td>
<td>2 (4.2)</td>
</tr>
</tbody>
</table>

* Values are numbers of patients (%).
† Timing of latest follow-up ranged from 2 to 16 years after surgery (average 7 years).

![FIG. 2. Effect of MVD on WHO hypertension grades over time, with delayed improvements. One year after MVD, the grades were significantly lower (p < 0.0001). The same held true at the most recent follow-up (p < 0.0001). However there was no statistically significant difference between 1 year and latest follow-up (p = 0.12, chi-square test).](image-url)
The question of undertreatment of hypertension prior to MVD surgery has to be raised. It is true that with antihypertensive treatment 38 of our patients had WHO Grade 1 hypertension, 9 had Grade 2, and 18 still had unstable BP. Notably, in most patients hypertension was severe (Grade 2 or 3 in 54%) and unstable (in 80%) before introduction of the medical treatment. After medical treatment was initiated, BP stabilized in 21 patients, and the average WHO grade improved from 1.63 to 1.19. We did not critically evaluate the antihypertensive treatment prescribed by the GPs, but our institution’s anesthesiologist checked the adequacy of treatment on the occasion of the preanesthesia outpatient clinic visit. To avoid introducing bias in the evaluation of the MVD effect, no change was made to the preoperative antihypertensive treatment.

Although the 48 patients enrolled in this study were operated on for a disease other than hypertension, namely HFS, we estimate that the favorable effect obtained by MVD on BP allows for consideration of MVD as a potential treatment for hypertension in cases in which it is likely to be neurogenic and due to vascular compression at the brainstem. Our results corroborate the pioneering work of Jannetta’s group26,27 and the results obtained in Falbusch’s series.

In all of our patients, surgical exploration was conducted in the same manner as for CN VII REZ decompression for sole HFS: first, exposure of the CN X–IX rootlets and, deeply, the lateral medullary sulcus, and then, upward, exposure of the CN VII REZ at the brainstem. Whatever the responsible artery (or arteries)—VA/BA, AICA, or PICA (the latter being the most frequent)—the compression was always found ventral to the CN X–IX REZ and ventrocaudal to the CN VII REZ. In 40% of the cases, more than one vessel was considered likely to be causing compression.

Of paramount importance, decompression of the CN X–IX REZ and adjacent ventrolateral medulla did not require more extensive exposure than the exposure required for HFS treatment. As with current decompression for HFS, the approach was inferolateral to the cerebellum to open the arachnoid, first posteriorly to the CN X–IX rootlets and to reach their REZ ventrally, and then to the CN VII REZ ventrocaudally. The trajectory was infralfoccular, along the choroid plexus, and obliquely, from below, so as not to stretch the CN VIII nerve complex and the labyrinthine artery.

Although not the topic of this paper, the effects of MVD on HFS were also evaluated. A satisfactory outcome was obtained in 87.5% of the patients.

According to classical anatomical/physiological knowledge, neurogenic hypertension is more likely to occur when dysfunction involves the left side of the brainstem (see Sindou, 2015,51 for review). In our series of 48 patients, the left side was implicated in 62.5%. This percentage is quite similar to the percentage (61%) in our group of 153 patients affected with HFS without hypertension (p = 0.83). In our series, efficacy of the decompression on hypertension was not significantly different between sides (p = 0.14). However, the percentage of normalization of BP without the need to maintain treatment was slightly better in the patients with the pathology on the left side (36.7%) than in those with the pathology on the right (16.7%), although this difference was not statistically significant.

Several publications have addressed the question of the prevalence of hypertension in patients with HFS compared with the general population of the same age range, with some investigating the side of the potentially responsible NVC by means of MRI. While some reported studies showed a higher prevalence of hypertension in patients with HFS than in control groups37,40 (as high as in 67% in patients with HFS46), others did not find any statistically significant differences (Colosimo et al., 47.3% vs 52.7%;13,14 and Tan et al., 42.7% vs 39.1%). Discrepancies between these studies might be due to bias in methodology: prevalence studies were retrospective and/or lacked proper matching with controls. In our global series of patients referred for surgery for their HFS, the percentage of patients with hypertension was 23.8% (n = 48). Hypertension was present in 26.11% of the patients with left-sided HFS and in 20% of those with right-sided HFS, which is not a statistically significant difference.

In an important study by Nakamura et al.37 there was no significant difference in prevalence of hypertension between patients with HFS (n = 82) and a control group without HFS (n = 82, matched for age and sex): 39% versus 29.3% (p = 0.19). There was also no difference in the prevalence of hypertension between the patients with left-sided (n = 44) and right-sided (n = 38) HFS: 32% versus 47%. But there was a significant difference when the side of the HFS and the presence or absence of hypertension were considered together; vascular compression at the ventrolateral medulla was observed on MRI in 86% of the patients with left HFS who had hypertension (n = 14) versus only 33% of the patients with left HFS without hypertension (n = 30) (p = 0.0012). There was no such significant difference in patients with right HFS (p = 0.18). Nakamura et al. concluded that these findings are of clinical importance, at least for the patients harboring left HFS and hypertension, and also for those with sole essential hypertension provided MRI shows vascular compression at the brainstem.

In a previously studied personal series of 362 patients affected with trigeminal neuralgia who underwent MVD, 26.8% of the patients had hypertension, and the average age

### TABLE 5. Complications associated with combined MVD of CN IV REZ, CN IX–X REZ, and ventrolateral medulla in 48 patients

<table>
<thead>
<tr>
<th>Complication</th>
<th>No. of Patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mortality</td>
<td>None</td>
</tr>
<tr>
<td>Neurological morbidity</td>
<td></td>
</tr>
<tr>
<td>Difficulty in swallowing, vocal cord paresis</td>
<td>T: 2; P: 1 (2%)</td>
</tr>
<tr>
<td>Hearing loss</td>
<td>P: 2 (4%)</td>
</tr>
<tr>
<td>Dizziness</td>
<td>P: 1 (2%)</td>
</tr>
<tr>
<td>Facial paresis</td>
<td>T: 2</td>
</tr>
<tr>
<td>Wound complications</td>
<td></td>
</tr>
<tr>
<td>Rhinorrhea</td>
<td>T: 1</td>
</tr>
<tr>
<td>Pseudomeningocele</td>
<td>T: 1</td>
</tr>
<tr>
<td>Infection (antibiotics)</td>
<td>T: 1</td>
</tr>
<tr>
<td>Systemic complications</td>
<td>None</td>
</tr>
</tbody>
</table>

P = permanent complication; T = transient.
of this subgroup was 61 years. These findings do not differ statistically in comparison with the findings for our series of 201 MVD for HFS, with 23.8% of the patients having hypertension at an average age of 53 (chi-square p = 0.44). The influence of MVD on hypertension in association with trigeminal neuralgia was not studied in our series. Of note, while the ventrolateral medulla was decompressed in the patients with HFS, for patients with trigeminal neuralgia, the ventrolateral medulla was not even explored at surgery because of the limited microsurgical exposure. In addition, a large number of studies were launched to evaluate the validity of MRI to identify NVC that might be causing hypertension. However, according to a recent meta-analysis, significance was absent when analysis was confined to prospective studies (p = 0.178 for prospective vs p = 0.001 for retrospective studies), making the predictive value of MRI for selecting patients relatively uncertain.

Furthermore, a major limitation for MRI screening is the difficulty of discriminating whether a detected elongated arterial loop in relation with the ventrolateral medulla and adjacent CN IX–X REZ is the cause or the consequence of the raised BP. Of the publications with information on the side of the compression, a higher rate of left-sided over right-sided vascular contact/compression was found in patients with essential hypertension. However, according to a recent meta-analysis, significance was absent when analysis was confined to prospective studies (p = 0.0178 for prospective vs p = 0.001 for retrospective studies), making the predictive value of MRI for selecting patients relatively uncertain.

Conclusions

Arguments that vascular compression of the brainstem at the level of the CN IX–X REZ and adjacent ventrolateral medulla may be involved in some forms of hypertension seem convincing enough to incite the neurosurgical community to work further on vascular decompression as a possible treatment option for patients diagnosed with essential hypertension who may in fact have neurogenic hypertension due to vascular compression. The main problem remains patient selection. MR images with high-resolution sequences allow identification of NVC with high sensitivity and specificity, but evidence of vascular contact/compression on MRI can well be the consequence of the elevated BP as well as the cause or a favoring factor of the hypertension disease. In spite of the large number of studies, the problem is still not solved. Nevertheless, we think that in patients in whom medical treatment does not control BP, consideration of decompressive surgery might be justified, provided imaging shows a vascular conflict that is likely to be responsible. The time has come for working groups, together with specialists in hypertension, to establish criteria for potential candidates for this treatment: patients whose hypertension has clinical peculiarities and/or pharmacological features in favor of a neurogenic origin and in whom imaging shows clear-cut evidence of vascular compression. Thus, studies could be launched with standardized protocols in patients with uncontrolled, unstable hypertension.

Acknowledgment

We thank Dr. Evelyne Decullier for her kind help with statistical analysis.

References

15. Dahlström A, Fuxe K: Evidence for the existence of mono-
amine-containing neurons in the central nervous system. I. Demonstration of monoamines in the cell bodies of brain-
19. European Society of Hypertension/European Society of Cardiology Hypertension Guidelines Committee: Practice guidelines for primary care physician: 2003 ESH/ESC hyp-
22. Granata AR, Ruggiero DA, Park DH, J oh TH, Reis DJ: Lesions of epinephrine neurons in the rostral ventrolateral me-
dulla abolish the vasodepressor components of baroreflex and cardiopulmonary reflex. Hypertension 5:V80–V84, 1983.
23. Hökfelt T, Fuxe K, Goldstein M, Johansson O: Immunohisto-
27. Jannetta PJ, Segal R, Wolfson SK Jr: Neurogenic hyperten-
30. Leal PR, Hermier M, Froment JC, Souza MA, Cristina-Filho G, Sindou M: Preoperative demonstration of the neurovas-
32. Levy EI, Clyde B, McLaughlin MR, Jannetta PJ: Microvas-
33. Levy EI, Scarrow AM, Jannetta PJ: Microvascular decom-
37. Nakamura T, Osawa M, Uchiyama S, Iwata M: Arterial hy-
41. Polo G, Fischer C, Sindou MP, Marneffe V: Brainstem audi-
43. Ross CA, Ruggiero DA, J oh TH, Park DH, Reis DJ: Arden-
line synthesizing neurons in the rostral ventrolateral me-
45. Säglitz SA, Gaab MR: Investigations using magnetic reso-
47. Segal R, Gendell HM, Canfield D, Duiovsky M, Jannetta PJ: Cardiovascular response to pulsatile pressure applied to ventr-
51. Sindou M: Is there a place for microsurgical vascular decom-
pression of the brainstem for apparent essential blood hyper-

Author Contributions
Conception and design: Sindou. Acquisition of data: Sindou, Mahmoudi. Analysis and interpretation of data: all authors. Drafting the article: Sindou, Mahmoudi. Critically revising the article: Sindou. Reviewed submitted version of manuscript: Sindou, Brînzeu. Approved the final version of the manuscript on behalf of all authors: Sindou. Statistical analysis: Brînzeu. Administrative/technical/material support: all authors. Study supervision: Sindou.

Supplementary Information
Previous Presentation
 Portions of this work have been presented in the form of oral presentations to the annual reunion of the French Speaking Society of Neurosurgery: “Reunion annuelle d’hiver de la SNCLF. Reunion annuelle de Paris.” Carrousel du Louvres, Paris, France, November 26–28, 2012.

Correspondence
Marc Sindou, Department of Neurosurgery, University of Lyon 1, Hôpital Neurologique “Pierre Wertheimer,” Groupement Hospitalier EST, 59 Blvd. Pinel, Lyon 69003, France. email: marc.sindou@chu-lyon.fr.